No­vo Nordisk bolts on a ‘holy grail’ oral de­liv­ery plat­form in $1.8B buy­out

A lit­tle over a year af­ter No­vo Nordisk shook up the big di­a­betes mar­ket with the ap­proval of oral semaglu­tide, the phar­ma ma­jor is grab­bing the tech used to con­vert the drug from a bi­o­log­ic in­to a ‘holy grail’ oral treat­ment in a $1.8 bil­lion buy­out.

No­vo says it is pay­ing $1.35 bil­lion in cash for all shares of Emi­sphere with an­oth­er $450 mil­lion be­ing shelled out to buy the roy­al­ty stream due to MHR Fund Man­age­ment — Emi­sphere’s biggest share­hold­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER